KOL Views: Can Eli Lilly turn Reyvow into more than a niche acute migraine drug?

The FDA approved Eli Lilly’s Reyvow (lasmiditan) last week for the acute treatment of migraine. The big question is how well the serotonin 5-HT1F, which comes with a notable risk of dizziness and drowsiness, will compete for scripts with the cheap and well-established triptans that come with plenty of drawbacks of their own.

To provide FirstWord readers with rapid feedback on how Reyvow will impact the treatment landscape in acute migraine, we are hosting an expert call with a key opinion leader (KOL) later this week.

Key topics that will be discussed during the call include, among other things… how are acute migraine patients currently managed; where will Reyvow initially fit into the treatment algorithm; how will Reyvow’s tolerability profile, and notably its association with dizziness and drowsiness, impact your prescribing decisions; how will you decide between triptans and Reyvow; what patient subsets would be ideal early adopters of Reyvow and what proportion of the acute migraine market do they represent; do you expect that some, most or all acute migraine patients will eventually cycle through Reyvow; how much of a concern is the risk of medication overuse headaches with Reyvow; what would need to happen for Reyvow to displace triptans as first choice treatment in some, most or even all patients; given its unique mechanism of action, might Reyvow be used in combination with other drugs; how would the availability of small molecule CGRP inhibitors impact like Allergan’s ubrogepant and/or Biohaven’s rimegepant impact the use of Reyvow; are preventative therapies like the anti-CGRP mAbs having any impact on use of acute migraine drugs; and will Eli Lilly’s ability to offer Reyvow and an anti-CGRP mAb make you any more likely to reach for Emgality (galcanezumab)?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the evolving treatment paradigm for migraine.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.